- Home
- INVE vs ACHV Comparison
INVE vs ACHV Comparison
Compare INVE & ACHV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INVE
- ACHV
- Stock Information
- Founded
- INVE 1990
- ACHV N/A
- Country
- INVE United States
- ACHV United States
- Employees
- INVE N/A
- ACHV N/A
- Industry
- INVE Computer peripheral equipment
- ACHV Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- INVE Technology
- ACHV Health Care
- Exchange
- INVE Nasdaq
- ACHV Nasdaq
- Market Cap
- INVE 74.2M
- ACHV 72.5M
- IPO Year
- INVE 1997
- ACHV N/A
- Fundamental
- Price
- INVE $3.50
- ACHV $2.31
- Analyst Decision
- INVE Strong Buy
- ACHV Strong Buy
- Analyst Count
- INVE 3
- ACHV 3
- Target Price
- INVE $6.50
- ACHV $14.33
- AVG Volume (30 Days)
- INVE 99.0K
- ACHV 1.3M
- Earning Date
- INVE 08-07-2025
- ACHV 08-12-2025
- Dividend Yield
- INVE N/A
- ACHV N/A
- EPS Growth
- INVE N/A
- ACHV N/A
- EPS
- INVE 3.12
- ACHV N/A
- Revenue
- INVE $25,239,000.00
- ACHV N/A
- Revenue This Year
- INVE N/A
- ACHV N/A
- Revenue Next Year
- INVE $9.00
- ACHV N/A
- P/E Ratio
- INVE $1.12
- ACHV N/A
- Revenue Growth
- INVE N/A
- ACHV N/A
- 52 Week Low
- INVE $2.86
- ACHV $1.84
- 52 Week High
- INVE $4.35
- ACHV $5.31
- Technical
- Relative Strength Index (RSI)
- INVE 63.68
- ACHV 39.39
- Support Level
- INVE $3.10
- ACHV $2.02
- Resistance Level
- INVE $3.61
- ACHV $3.90
- Average True Range (ATR)
- INVE 0.14
- ACHV 0.26
- MACD
- INVE 0.04
- ACHV -0.10
- Stochastic Oscillator
- INVE 79.25
- ACHV 17.37
About INVE Identiv Inc.
Identiv Inc is a security technology company. It secures and manages access to physical places, things, and information. The company has one reportable segment: the IoT Business segment. Geographically, it generates maximum revenue from the Americas and also has a presence in Europe and the Middle East, and Asia-Pacific.
About ACHV Achieve Life Sciences Inc.
Achieve Life Sciences Inc is a specialty pharmaceutical company committed to advancing cytisinicline as a widely available treatment option to help people battling nicotine addiction. It is an established smoking cessation treatment that has been approved and marketed in Central and Eastern Europe. Achieve's focus is to address the smoking health epidemic through the development and commercialization of cytisinicline. It has one operating segment, dedicated to the development and commercialization of cytisinicline for niceon.